NICE stands firm on Alimta for maintenance
This article was originally published in Scrip
Executive Summary
Despite Eli Lilly revising its original submission, NICE – the health technology assessment body for England and Wales – has issued draft guidance not recommending Alimta (pemetrexed) for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in people whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.